18857-02-8

Basic information

• Product Name: 3-methoxybut-1-yne
• CAS NO: 18857-02-8
• Molecular Formula: C₅H₈O
• Molecular Weight: 84.1164
• Mol File: 18857-02-8.mol

Chemical Properties

• Boiling Point: 79.7°C at 760 mmHg
• Density: 0.828g/cm³
• Vapor Pressure: 97.3mmHg at 25°C
• Refractive Index: 1.402
• CAS DataBase Reference: 3-methoxybut-1-yne(CAS DataBase Reference)
• NIST Chemistry Reference: 3-methoxybut-1-yne(18857-02-8)
• EPA Substance Registry System: 3-methoxybut-1-yne(18857-02-8)

Safety Data

• Hazardous Substances Data: 18857-02-8(Hazardous Substances Data)

Upstream product

• 2028-63-9 but-3-yn-2-ol 
• 77-78-1 dimethyl sulfate 
• 136157-90-9 3,3-dimethoxy-1-butyne 
• 75-18-3 dimethylsulfide 

Downstream Products

• 67280-39-1 N-(4-methoxy-2-pentynyl)-N-methylbenzylamine 
• 17742-05-1 3-methoxybutan-2-one 
• 330558-57-1 methyl 3-(4-fluorophenyl)-1,2-oxazole-5-carboxylate 
• 1081-30-7 3-phenyl-isoxazole-5-carboxylic acid methyl ester 
• 1262034-09-2 C₁₆H₂₁NO₃ 
• 51233-49-9 4-Methoxy-3-methyl-1-phenyl-pent-1-yn-3-ol 
• 89358-54-3 4-diphenylphosphinoyl-2-methoxy-3-methylhexan-3-ol 
• 69930-76-3 2-diphenylphosphinoyl-4-methoxy-3-methylpentan-3-ol 
• 344871-55-2 1-diphenylphosphinoyl-3-methoxy-2-methylbutan-2-ol 

Relevant articles and documents

PHOTOPROTECTIVE COMPOSITIONS CONTAINING MALASSEZIA-DERIVED COMPOUNDS AND/OR CHEMICAL ANALOGS THEREOF

The present invention relates to compounds, compositions, and methods for modulating skin pigmentation and treating or preventing UV-induced skin damage, erythema, aging of the skin, sunburn, and hyperpigmentation in a subject. The compounds, compositions, and methods of the present invention generally involve Malassezia-derived compounds, including malassezin and indirubin, and/or chemical analogs thereof. Other applications of the compounds and compositions disclosed herein include, but are not limited to, improving hyperpigmentation caused by a hyperpigmentation disorder, inducing melanocyte apoptosis, and modulating arylhydrocarbon receptor (AhR) activity, melanogenesis, melanin production, melanosome biogenesis, melanosome transfer, melanocyte activity, and melanin concentration.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Resolution of carboxylic acids using copper(I)-promoted removal of propargylic esters under neutral conditions

A method for the optical resolution of carboxylic acids is described. Condensation of racemic carboxylic acids with chiral terminal propargyl alcohols gave separable diastereomeric esters. Chromatographic separation followed by heating the individual diastereomers in methanol with catalytic copper(I) halide regenerated the carboxylic acids in good yields and in enantiomeric ratios of ?94%. This method is particularly useful for the resolution of carboxylic acids that are incompatible with conventional ester hydrolysis.

QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER

The invention concerns quinazoline derivatives of Formula (I) wherein each of Z, m, R1, n, R3,Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.

Antiulcer compounds having a substituted alkynyl or quinoxaline nucleus and methods of making thereof

This invention relates to a novel compound which is useful as a drug in preventing and/or treating peptic ulcer-related diseases, to a production process thereof and to a pharmaceutical composition containing the same. Particularly, it provides a compound which has a specified substituted alkynylpyrazine nucleus or a specified substituted alkynylquinoxaline nucleus, represented by the following formula (I) STR1 wherein A is represented by the following formula (II) or (III) STR2 and R1 is represented by the following formula (IV), STR3 and the salts thereof, a production process thereof and a pharmaceutical composition containing the same. The inventive compound is useful as a drug in preventing and/or treating peptic ulcer-related diseases.

Catecholborane reductive cleavage of allyl and propargyl acetals and ketals: A simple route to allyl and prop-2-ynyl ethers

The chemoselective conversion of allyl and prop-2-ynyl acetals as well as ketals by reductive cleavage with catecholborane into the corresponding allyl and prop-2-ynyl ethers is described.

Synthesis of β-(Diphenylphosphinoyl) Ketones

The title compounds may be made by addition of phosphorus nucleophiles (Ph2PO-, Ph2POMgX, Ph2PCl) to enones, by addition of phosphorus-stabilised carbanions to a α-carbonyl cation equivalents (2,3-dichloropropene, epoxides, and α-MeO-ketones) and by oxidation of allyl diphenylphosphine oxides.